Top Page
Imugene
(Sydney:IMU)
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Imugene Business Overview & Revenue Model
Imugene Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.14M | 4.40M | 4.97M | 11.78M | 12.97M | 7.23M |
| Gross Profit | 2.79M | 4.40M | 4.97M | 9.57M | 10.56M | 5.27M |
| EBITDA | -58.98M | -67.42M | -147.98M | -47.42M | -48.06M | -23.72M |
| Net Income | -58.50M | -69.02M | -149.68M | -37.91M | -37.87M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 67.67M | 83.59M | 151.40M | 197.06M | 147.61M | 71.81M |
| Cash, Cash Equivalents and Short-Term Investments | 14.14M | 21.94M | 94.54M | 153.15M | 99.89M | 29.49M |
| Total Debt | 5.02M | 10.65M | 2.19M | 553.47K | 673.43K | 271.03K |
| Total Liabilities | 25.80M | 38.56M | 33.14M | 7.44M | 8.90M | 6.79M |
| Stockholders Equity | 41.87M | 45.03M | 118.25M | 189.63M | 138.70M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -59.70M | -90.03M | -108.80M | -29.78M | -30.93M | -18.58M |
| Operating Cash Flow | -62.92M | -75.57M | -101.73M | -29.78M | -30.67M | -13.13M |
| Investing Cash Flow | 2.86M | -12.70M | -7.25M | 9.63K | -414.16K | -5.48M |
| Financing Cash Flow | 40.66M | 17.37M | 49.43M | 82.98M | 101.35M | 17.99M |
Imugene Technical Analysis
Imugene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$94.16M | -11.14 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$66.25M | -6.30 | -49.72% | ― | ― | 10.78% | |
46 Neutral | AU$109.81M | -2.80 | -81.03% | ― | -20.79% | 73.98% | |
41 Neutral | AU$76.13M | -6.67 | -42.68% | ― | ― | 63.46% | |
41 Neutral | AU$130.13M | -3.95 | ― | ― | ― | 0.66% | |
40 Underperform | AU$65.91M | -0.92 | -83.09% | ― | ― | 55.94% |
Imugene Corporate Events
Imugene Limited, a clinical-stage immuno-oncology company, will present clinical data on its lead program azer-cel, an allogeneic off-the-shelf CAR T cell therapy, at the TD Cowen 46th Annual Health Care Conference in Boston. Chief Medical Officer John Byon is scheduled to present on 2 March 2026, with the presentation to be made available on the company’s website afterward.
The TD Cowen conference is one of the largest global healthcare investment forums, gathering biotechnology and pharmaceutical companies alongside institutional investors and sector specialists. Imugene’s participation underscores its efforts to showcase its CAR T platform to the investment community and industry peers, potentially strengthening its visibility and positioning in the competitive immuno-oncology and cell therapy landscape.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.23 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has received an A$2.74 million research and development tax refund from the Australian Government’s R&D Tax Incentive program for the 2025 financial year. The non-dilutive funding, which includes interest, strengthens the company’s cash position and will support the continued clinical development of its immuno-oncology pipeline at a pivotal time following a recent U.S. FDA meeting and positive clinical results, potentially reinforcing its position in the competitive cancer therapy space.
This refund underscores the importance of government incentives in sustaining high-cost, high-risk oncology research and may help Imugene progress its CAR T and oncolytic virotherapy programs without immediately resorting to additional capital raising. For shareholders and other stakeholders, the payment provides incremental financial flexibility as the company advances toward potential value-inflection milestones in its clinical trials.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene reported a net loss attributable to members of $37.8 million for the half year ended 31 December 2025, representing a 22% reduction in losses compared with the prior corresponding period. The company recorded no revenue from ordinary activities, did not declare or pay any dividends, and saw its net tangible assets per security decline to 4.7 cents from 12.6 cents a year earlier, indicating a weaker balance sheet for investors despite no changes in its controlled entities.
Management referred investors to the accompanying review of operations, directors’ report, and financial statements for detailed explanations of the results and operational progress. The absence of dividends and lower asset backing underscores that Imugene remains in an investment and development phase, with shareholder returns currently dependent on future clinical and commercial milestones rather than near-term earnings or distributions.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has notified holders of its listed options on the ASX, trading under ticker IMUO, that these securities are exercisable at $0.43 each and will expire at 5:00 p.m. AEDT on 30 March 2026. Official quotation of the options will cease at the close of trading on 24 March 2026, four business days prior to expiry.
Option holders who wish to convert their holdings into Imugene shares must lodge a completed notice of exercise of options form and payment before the expiry date. The move formalises the timetable for the company’s listed options, giving investors a clear window to decide on exercising their rights and potentially increasing Imugene’s equity base ahead of the lapse of these instruments.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has notified the market of the issue of 400 unquoted options expiring on 30 June 2028 with an exercise price of $0.86, issued on 16 February 2026. These options, documented via an Appendix 3G, form part of previously announced transactions and are not quoted, nor intended to be quoted, on the ASX, indicating a minor adjustment to the company’s capital structure rather than a shift in strategic direction.
The small scale and unquoted nature of the new options suggest limited immediate impact on existing shareholders but reflect ongoing use of equity-based instruments within Imugene’s broader financing or incentive frameworks. By maintaining transparent disclosure of such issuances, Imugene continues to align with ASX regulatory requirements while fine-tuning its balance between dilution and capital or incentive needs.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero coupon convertible notes, increasing its share capital without undertaking a separate disclosure to investors under the fundraising provisions of the Corporations Act. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations and stated there is no excluded information requiring disclosure, signalling a routine capital structure adjustment rather than a change in strategic direction, but one that modestly dilutes existing shareholders while converting debt-like instruments into equity.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene reported strong Phase 1b clinical data for its allogeneic CD19 CAR T therapy azer-cel, achieving an 82% overall response rate in relapsed/refractory DLBCL, including seven complete and seven partial responses among 17 patients, with the first patient dosed in 2024 remaining cancer-free for more than 21 months and an 83% response rate recorded in a CAR T–naïve cohort of heavily pre-treated lymphoma patients. The company also highlighted regulatory and strategic milestones, including favourable FDA meeting minutes providing a pathway to a pivotal azer-cel trial, selection of azer-cel for an oral presentation at the ASH Annual Meeting, a new collaboration with JW Therapeutics to advance its onCARlytics program, amendments to convertible notes to improve cash flow, and expectations that operating costs will be about 50% lower than the prior financial year, collectively strengthening its clinical and financial positioning.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero coupon convertible notes, expanding its share capital under ASX code IMU. The company confirmed the issuance was conducted without a prospectus under the Corporations Act disclosure exemptions, while affirming ongoing compliance with its financial reporting and continuous disclosure obligations and stating that no excluded information is being withheld from the market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has applied to the ASX for quotation of 1,736,111 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The additional shares, issued on 7 January 2026, modestly expand Imugene’s quoted capital base and reflect ongoing utilisation of equity-linked incentives or funding structures, with implications for shareholder dilution but also providing incremental capital support for the company’s biotechnology development activities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has reported the cessation of several classes of equity incentives listed on the ASX, including multiple series of options and restricted stock units that have lapsed or expired unexercised as of 5 January 2026. The announcement details that these securities ceased because the performance or vesting conditions were not met or became incapable of being satisfied, resulting in the expiry of a total of more than one million potential securities and effectively reducing the company’s pool of outstanding equity-based instruments, which may have implications for future dilution and the structure of employee and executive incentive arrangements.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has applied for quotation on the ASX of 929,427 new ordinary fully paid shares, issued on 6 January 2026 following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects ongoing capital management and shareholder participation in equity-linked instruments, incrementally broadening the company’s free float and potentially enhancing liquidity in its stock without materially altering its overall capital structure.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene has announced the resignation of Chief Operating Officer Dr Bradley Glover, who is stepping down to focus on other business interests after playing a key role in advancing the company’s oncology programs, particularly the development of its CAR T cell therapy azer-cel. The company stated that responsibilities will be transitioned without disrupting operations or ongoing programs, and the board has publicly thanked Dr Glover for his contributions, signalling a managed leadership change designed to preserve momentum across its clinical pipeline and reassure investors and partners about continuity.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero-coupon convertible notes, expanding its share capital without undertaking a separate disclosure to investors. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations under the Corporations Act and stated there is no excluded information that must be disclosed, signalling routine capital management with no undisclosed material developments for shareholders.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has applied for quotation on the ASX of 1,736,111 new fully paid ordinary shares, with an issue date of 22 December 2025. The additional securities, issued under a previously announced transaction, will increase the company’s quoted share capital, potentially enhancing liquidity in its stock and supporting ongoing corporate and capital management activities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has notified the market of the issue of 88,233 restricted stock units and 875,675 performance rights awards under its employee incentive scheme, effective 15 December 2025. The unquoted equity issuance, which will not be listed on the ASX, underscores the company’s continued use of equity-based compensation to attract and retain talent, aligning staff incentives with long-term shareholder value and supporting the execution of its strategic and clinical development objectives.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the cessation of a small tranche of its convertible notes, with 25 IMUAAR convertible securities cancelled by mutual agreement between the company and the noteholder on 18 December 2025. The move marginally simplifies Imugene’s capital structure and slightly reduces its outstanding convertible debt, though the limited size of the cancellation suggests a modest immediate impact on the company’s overall financing position.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has notified the market of the issue of new unquoted securities, comprising 25 new convertible notes and 7,812,500 new warrants, with an issue date of 18 December 2025. These instruments, which are not intended to be quoted on the ASX, form part of previously announced transactions and indicate the company is continuing to utilise structured financing to support its operations and development programs, with potential future dilution implications for existing shareholders depending on conversion and exercise terms.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has reported a change in director Paul Hopper’s interests in the company’s securities following the issue of additional performance rights under its Employee Share Option Plan. Hopper, who holds both direct and indirect share interests, received 124,054 new performance rights at no cost, increasing his total performance rights holding to 260,320, in line with shareholder approval granted at the company’s 13 November 2025 annual general meeting. The transaction, which did not involve any disposal of securities or trading during a closed period, reflects ongoing use of equity-based incentives to align director remuneration with shareholder interests.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a proposed issue of new securities, comprising up to 25 new convertible notes and 7,812,500 new warrants, with a proposed issue date of 18 December 2025. The capital raising, to be conducted via a placement or similar structure, underscores the company’s ongoing use of equity-linked instruments to fund its operations and growth initiatives, with potential implications for its capital structure and existing shareholders as the additional securities come on line.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced amendments to its existing convertible notes and introduced new convertible notes and warrants valued at A$2.5 million and A$2.75 million, respectively, in collaboration with CVI Investments, Inc. The financial adjustments aim to enhance the company’s cash flow management and provide flexibility, supporting operational stability during the term of the notes. By issuing the new financial instruments under its existing ASX Listing Rule capacity without needing shareholder approval, Imugene strengthens its financial standing and market positioning in the immuno-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced significant progress in its azer-cel program, with strong clinical data and FDA support to advance to the next trial stage. The company expects to reduce operating costs by 50% in the coming year and has formed a strategic collaboration with JW Therapeutics to leverage commercial CAR T infrastructure. The FDA’s positive feedback on Imugene’s dosing regimen and patient population for azer-cel, along with promising clinical results, positions the company to explore additional registrational opportunities, potentially enhancing its market position and offering new hope for blood cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced a webinar to discuss positive feedback from the FDA regarding their azer-cel program, highlighting its potential to advance into pivotal studies. This development underscores the program’s clinical and commercial promise, potentially strengthening Imugene’s position in the immuno-oncology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has received support from the FDA to advance its azer-cel treatment into a Phase 3 registrational study, targeting patients with relapsed DLBCL after CAR-T therapy. The FDA’s endorsement of Imugene’s dual endpoint strategy and Chemistry Manufacturing Controls readiness signifies a significant opportunity for the company in a high-need setting, potentially enhancing its market position in the immune-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.